UroGen Pharma Ltd (URGN) Implied Volatility Current

Tracking URGN implied volatility helps you identify when options premiums on UroGen Pharma Ltd are historically cheap or expensive, and where the best trades are hiding. UroGen Pharma Ltd implied volatility reflects the market's expectation of future price movement: when URGN IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor UroGen Pharma Ltd's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For URGN, tracking metrics like URGN IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on URGN signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer.

The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where URGN implied volatility sits today versus where it has been. Our scanner ranks UroGen Pharma Ltd implied volatility against its historical range, surfaces extremes in URGN IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether UroGen Pharma Ltd IV is rich or cheap — measure it, then act on it.